Bigalke H - Search Results

1

Botulism type B presenting as pure autonomic dysfunction.

Merz B, Bigalke H, Stoll G, Naumann M. Merz B, et al. Among authors: bigalke h. Clin Auton Res. 2003 Oct;13(5):337-8. doi: 10.1007/s10286-003-0118-2. Clin Auton Res. 2003. PMID: 14564656

2

Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin.

Naumann M, Toyka KV, Mansouri Taleghani B, Ahmadpour J, Reiners K, Bigalke H. Naumann M, et al. Among authors: bigalke h. J Neurol Neurosurg Psychiatry. 1998 Dec;65(6):924-7. doi: 10.1136/jnnp.65.6.924. J Neurol Neurosurg Psychiatry. 1998. PMID: 9854974 Free PMC article.

3

Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure?

Dressler D, Zettl U, Benecke R, Bigalke H. Dressler D, et al. Among authors: bigalke h. Mov Disord. 2000 Nov;15(6):1279-81. doi: 10.1002/1531-8257(200011)15:6<1279::aid-mds1040>3.0.co;2-4. Mov Disord. 2000. PMID: 11104225 No abstract available.

4

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.

Dressler D, Bigalke H, Benecke R. Dressler D, et al. Among authors: bigalke h. J Neurol. 2003 Aug;250(8):967-9. doi: 10.1007/s00415-003-1129-6. J Neurol. 2003. PMID: 12928917 Corrected and republished.

5

A long-term follow-up of botulinum toxin A in cervical dystonia.

Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. Mohammadi B, et al. Among authors: bigalke h. Neurol Res. 2009 Jun;31(5):463-6. doi: 10.1179/174313209X405137. Epub 2009 Mar 11. Neurol Res. 2009. PMID: 19278576

6

Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.

Birklein F, Walther D, Bigalke H, Winterholler M, Erbguth F. Birklein F, et al. Among authors: bigalke h. Ann Neurol. 2002 Jul;52(1):68-73. doi: 10.1002/ana.10243. Ann Neurol. 2002. PMID: 12112049

7

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Albrecht P, Jansen A, Lee JI, Ringelstein M, Aktas O, Hartung HP, Bigalke H, Hefter H. Albrecht P, et al. Among authors: bigalke h. Neurology. 2019 Oct 22;93(17):767-768. doi: 10.1212/WNL.0000000000008378. Neurology. 2019. PMID: 31636231 No abstract available.

8

Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?

Dressler D, Münchau A, Bhatia KP, Quinn NP, Bigalke H. Dressler D, et al. Among authors: bigalke h. Eur Neurol. 2002;47(2):118-21. doi: 10.1159/000047963. Eur Neurol. 2002. PMID: 11844901

9

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Göschel H, et al. Among authors: bigalke h. Exp Neurol. 1997 Sep;147(1):96-102. doi: 10.1006/exnr.1997.6580. Exp Neurol. 1997. PMID: 9294406 Clinical Trial.

10

Clinical impact of antibody formation to botulinum toxin A in children.

Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, Linder M, Kirschner J, Berweck S, Korinthenberg R, Heinen F, Fietzek UM. Herrmann J, et al. Among authors: bigalke h. Ann Neurol. 2004 May;55(5):732-5. doi: 10.1002/ana.20098. Ann Neurol. 2004. PMID: 15122715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters